Back to Results
First PageMeta Content
Pharmacology / Organic chemistry / Doripenem / Dosage forms / Ertapenem / Shionogi / Intravenous therapy / Carbapenem / Meningitis / Carbapenem antibiotics / Medicine / Pyrrolidines


Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic, ® “Finibax 0.25g/0.5g for Intravenous Drip Infusion” and “Finibax® 0.25g Kit for Intra
Add to Reading List

Document Date: 2014-11-03 11:26:21

Open Document

File Size: 26,83 KB

Share Result on Facebook

City

Osaka / /

Company

Shionogi & Co. Ltd. / Corporate Communications Department Shionogi & Co. Ltd. / /

Country

Japan / /

Event

FDA Phase / /

/

IndustryTerm

treatment of infectious diseases / vial product / foreign healthcare reforms / with respect to product / /

MedicalCondition

Pseudomonas / infectious diseases / Purulent Meningitis / serious and intractable infections / /

Person

Isao Teshirogi / /

/

Position

President & CEO / /

Product

Finibax® / /

Technology

anti-infectives / 3g / /

SocialTag